# A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.

Study · id `cardio:ct-nct02607306` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02607306](<https://clinicaltrials.gov/study/NCT02607306>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02607306

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 819 participants.

## Technical summary

Registry record NCT02607306. Randomized; no masking; primary purpose treatment. Start 2015-11-18 (actual); primary completion 2017-12-15 (actual). Results posted on 2019-07-29.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 819 participants (enrolled count; ClinicalTrials.gov record NCT02607306, source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)
- Started: 2015-11-18 (actual) (ClinicalTrials.gov record NCT02607306, source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)
- Primary completion: 2017-12-15 (actual) (ClinicalTrials.gov record NCT02607306, source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)
- Completion: 2017-12-22 (actual) (ClinicalTrials.gov record NCT02607306, source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)
- Results first posted: 2019-07-29 (ClinicalTrials.gov record NCT02607306, source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02607306, source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02607306-2021-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
- Acronym: DUAL™ I Japan
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/liraglutide
- Intervention (Drug): insulin degludec
- Intervention (Drug): liraglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial (`cardio:pubmed-31407845`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 45737b2a2d2aee6e77e535384535c9d576c916ac807c6adeb92cbafb10a78fe8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
